Aptevo Therapeutics Inc. (APVO)
APVO moved a median of -0.89% 30 minutes after news, and -1.83% by the close. How APVO actually reacts to news — the realized, point-in-time move the market made, measured across 318 labeled events over the last three years with zero look-ahead.
APVO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 303 |
| 30-min | -0.89% | 34% | 318 |
| 60-min | -0.91% | 33% | 318 |
| to close | -1.83% | 40% | 317 |
| Middle 50% of APVO reactions | -3.78% to +1.07% |
|---|---|
| Median reaction (30-min) | -0.89% |
| Measured reactions | 318 |
Half of all Aptevo Therapeutics Inc. news events land between -3.78% and +1.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when APVO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APVO's baseline. Nothing else.
Recent APVO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting | Press release | ACCESS Newswire | +2.31% | +0.00% | |
| Form 8-K Aptevo Therapeutics Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | +0.00% | |
| Form S-8 Aptevo Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | — | +1.06% | |
| Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development | Press release | ACCESS Newswire | +1.06% | -2.66% | |
| Form 8-K Aptevo Therapeutics Inc. For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | -2.66% | |
| Form 8-K Aptevo Therapeutics Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | -2.66% | |
| Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | Press release | ACCESS Newswire | +0.95% | -18.96% | |
| Form 8-K Aptevo Therapeutics Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | -18.96% | |
| Form EFFECT Aptevo Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.95% | -18.96% | |
| Form DEF 14A Aptevo Therapeutics Inc. For: Sep 22 | SEC filing · Form DEF | SEC EDGAR | -0.82% | -4.10% | |
| Form D Aptevo Therapeutics Inc. | SEC filing · Form D | SEC EDGAR | — | +0.00% | |
| Form 8-K Aptevo Therapeutics Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -12.68% | |
| Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -12.68% | |
| Form S-1 Aptevo Therapeutics Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -12.68% | |
| Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | Press release | ACCESS Newswire | +0.29% | -13.27% | |
| Form 10-Q Aptevo Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.29% | -13.27% | |
| Form 8-K Aptevo Therapeutics Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | -13.27% | |
| Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds | Press release | ACCESS Newswire | +0.29% | -13.27% | |
| Form 8-K Aptevo Therapeutics Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | -13.27% | |
| Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds | Press release | ACCESS Newswire | -7.16% | -7.16% | |
| Form ARS Aptevo Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.98% | -3.19% | |
| Form DEF 14A Aptevo Therapeutics Inc. For: Jul 31 | SEC filing · Form DEF | SEC EDGAR | -0.98% | -3.19% | |
| Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | Press release | ACCESS Newswire | -1.77% | -3.88% | |
| Form 8-K Aptevo Therapeutics Inc. For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.47% | |
| Form S-8 Aptevo Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.77% | -3.88% | |
| Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors | Press release | ACCESS Newswire | +0.91% | +1.14% | |
| Form 8-K Aptevo Therapeutics Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | -1.11% | |
| Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer | Press release | ACCESS Newswire | +2.38% | +8.22% | |
| Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing | Press release | ACCESS Newswire | -7.64% | +0.00% | |
| Form 8-K Aptevo Therapeutics Inc. For: May 25 | SEC filing · Form 8-K | SEC EDGAR | +2.38% | +8.22% | |
| Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | Press release | ACCESS Newswire | -0.17% | +0.21% | |
| Form 10-Q Aptevo Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.84% | +0.31% | |
| Form 8-K Aptevo Therapeutics Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | +0.31% | |
| Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | Press release | ACCESS Newswire | -3.74% | +8.57% | |
| Form 8-K Aptevo Therapeutics Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -1.82% | |
| Aptevo Provides State of the Business Report and 2025 Financial Results | Press release | ACCESS Newswire | — | +3.68% | |
| Form 10-K Aptevo Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.16% | -5.11% | |
| Form 8-K Aptevo Therapeutics Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | -5.11% | |
| Aptevo to Participate in March 2026 Conferences | Press release | ACCESS Newswire | +1.81% | +1.58% | |
| Form 8-K Aptevo Therapeutics Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +2.43% | -12.30% | |
| Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% | Press release | ACCESS Newswire | -1.53% | -6.14% | |
| Form 8-K Aptevo Therapeutics Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.41% | |
| Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth | Press release | ACCESS Newswire | -2.99% | -8.03% | |
| Form 8-K Aptevo Therapeutics Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | -2.99% | -8.03% | |
| Form EFFECT Aptevo Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.62% | +3.86% | |
| Form S-1 Aptevo Therapeutics Inc. | SEC filing · Form S-1 | SEC EDGAR | -2.32% | -2.76% | |
| Form DEF 14A Aptevo Therapeutics Inc. For: Jan 23 | SEC filing · Form DEF | SEC EDGAR | — | -6.24% | |
| Form PRE 14A Aptevo Therapeutics Inc. For: Jan 16 | SEC filing · Form PRE | SEC EDGAR | -2.59% | +6.16% | |
| Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality | Press release | ACCESS Newswire | -5.20% | -1.53% | |
| Form 8-K Aptevo Therapeutics Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -5.20% | -1.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APVO section they belong to.
Where else APVO is measured.
APVO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 320 | -0.12% | 42% |
| Viking Therapeutics, Inc. (VKTX) | 319 | -0.60% | 43% |
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aptevo Therapeutics Inc.'s median reaction calculated?
Every labeled APVO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 318 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of APVO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APVO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.